trial
as of 2026-07-01Multiple Dose Study Evaluating the Safety and Tolerability of NSA-789
NCTId NCT00795730
at a glance
Phase 1 · Completed
Enrollment 24 (actual)
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer
Primary completion 2009-05
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
24 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-01
Primary completion
2009-05
Eligibility
ALL · 18 Years · 99 Years
Interventions & indications
Sponsors
Wyeth is now a wholly owned subsidiary of PfizerLead Sponsor
Sites
0 total
Facts & assertions
4 sourced
Enrollment
24
Phase
PHASE1
Primary Completion Date
2009-05
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication